A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-06-29) →
What happened
Aprogen Biologics updated the terms of convertible bonds to raise US$32.9M, about 199.4% of its market value.
For context, this raise equals about 199.4% of the company's market value, which is the rough scale of potential new-share dilution.
| Instrument | Convertible bonds |
|---|---|
| Raise amount | US$32.9M |
| vs. market value | 199.4% |
| Filed | 2026-06-24, [Amended] Material event report (convertible bonds) |
| Source | DART rcept 20260623000426 → open original filing |
Versions of this filing
- 2026-05-26Original
- 2026-06-02Amendment 1
- 2026-06-19Amendment 2
- 2026-06-24Amendment 3 (this page)
- 2026-06-29Amendment 4
Source: DART. Information only, not investment advice.